IM
Last reporting period 30 Sep, 2023
Updated —
Last price
—
Market cap $B
8.726
Exchange
XNAS - Nasdaq
0.61 B
Last period Cash and equivalents ,USD
100%
Cash and equivalents has increased in 5 years
What is Cash and equivalents ?
Cash is the amount of free cash on the company's accounts, as well as short-term liquid investments.
See also ImmunoGen
Company Analysis
IMGN valuation, rating, competitors, insights and company profile
Eyestock Rating
IMGN financial analysis by Eyestock methodology
Valuation
IMGN valuation using historical relative method
Statements
IMGN Income Statements, Balance Sheet and Cash Flow Statements
Dividends
IMGN dividend yield and annual dividend
Cash is the amount of free cash on the company's accounts, as well as short-term liquid investments.
ImmunoGen`s Cash and equivalents for the period ended 2023-09-30 are 0.61 B USD
